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ABSTRACT
PEL is a B-cell non-Hodgkin lymphoma, occurring predominantly as a lymphomatous 
effusion in body cavities, characterized by aggressive clinical course, with no standard 
therapy. Based on previous reports that PEL cells display a Warburg phenotype, we 
hypothesized that the highly hypoxic environment in which they grow in vivo makes 
them more reliant on glycolysis, and more vulnerable to drugs targeting this pathway. 
We established here that indeed PEL cells in hypoxia are more sensitive to glycolysis 
inhibition. Furthermore, since PI3K/Akt/mTOR has been proposed as a drug target in 
PEL, we ascertained that pathway-specific inhibitors, namely the dual PI3K and mTOR 
inhibitor, PF-04691502, and the Akt inhibitor, Akti 1/2, display improved cytotoxicity 
to PEL cells in hypoxic conditions. Unexpectedly, we found that these drugs reduce 
lactate production/extracellular acidification rate, and, in combination with the glycolysis 
inhibitor 2-deoxyglucose (2-DG), they shift PEL cells metabolism from aerobic glycolysis 
towards oxidative respiration. Moreover, the associations possess strong synergistic 
cytotoxicity towards PEL cells, and thus may reduce adverse reaction in vivo, while 
displaying very low toxicity to normal lymphocytes. Finally, we showed that the 
association of 2-DG and PF-04691502 maintains its cytotoxic and proapoptotic effect 
also in PEL cells co-cultured with human primary mesothelial cells, a condition known 
to mimic the in vivo environment and to exert a protective and pro-survival action. 
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All together, these results provide a compelling rationale for the clinical development 
of new therapies for the treatment of PEL, based on combined targeting of glycolytic 
metabolism and constitutively activated signaling pathways.
INTRODUCTION
Primary effusion lymphoma (PEL) is a rare 
subtype of B-cell non-Hodgkin lymphoma (B-NHL) 
whose primary etiological agent is Kaposi’s sarcoma-
associated herpesvirus human herpesvirus 8 (KSHV, 
or HHV-8), and is often co-infected with Epstein-Barr 
virus (EBV) [1–5]. This malignancy is characterized 
by a very aggressive clinical course, with median 
survival times of a few months upon conventional 
chemotherapy. Viral gene products have been reported 
to dysregulate cellular signaling pathways and to 
favor survival. Viral proteins such as K1 and vGPCR 
can activate the phosphatidylinositol-3-kinase/Akt/
mammalian target of rapamycin (PI3K/Akt/mTOR) 
pathway in B-lymphocytes and its constitutive 
activation was suggested to play a critical role in PEL 
cells growth and survival [6–8]. The efficacy of the 
mTOR inhibitor rapamycin, Sirolimus, in PEL cells in 
culture and in a xenograft PEL model, however, was 
limited by the rapid emergence of drug resistance [9]. 
Vertical targeting of the pathway at multiple levels by 
the dual PI3K/mTOR inhibitor NVP-BEZ235 gave 
more promising results [10]. In addition to its central 
role in promoting cell survival and inhibiting apoptosis 
[11–15], the alteration of intracellular signaling through 
the PI3K/Akt pathway is deemed crucial to achieve 
a cancer metabolic phenotype through the Warburg 
effect [16–20], i.e. the upregulation of glycolysis that 
allows the branching off of glycolytic intermediates 
to different anabolic pathways to sustain the higher 
demand of the transformed cells for metabolic inputs 
to promote proliferation [21–25]. Compared to primary 
B-cells, PEL cell lines are characterized by a glycolytic 
phenotype [26]; this in turn makes PEL cells sensitive 
to the glycolysis inhibitor 2-deoxyglucose (2-DG) 
under normoxic conditions [26, 27]. It should however 
be reminded that, in vivo, PEL develops in an hypoxic 
environment [28, 29], the body cavities. In our study 
we investigated the efficacy of a panel of glycolysis 
inhibitors against PEL cell lines in both normoxic and 
hypoxic conditions. On the other hand, because cellular 
responses to hypoxia may reduce chemotherapeutic 
sensitivity through diverse mechanisms acting on 
survival pathways, we addressed the effectiveness of 
drugs targeting various levels of the PI3K signaling 
cascade. Finally, we determined whether inhibition of 
both glycolysis and PI3K/Akt/mTOR-mediated survival 
results in a synergistic cooperation to induce more 
potent apoptosis and metabolic rerouting.
RESULTS
Glycolysis inhibitors are efficacious against PEL 
cell lines
PEL cells were claimed to display a Warburg 
phenotype, reflected in an elevated glycolytic activity 
under normoxic conditions, and inhibition of glycolysis 
was reported to be sufficient to reduce cell viability [26]. 
To define the metabolic profile of two representative PEL 
cell lines, BCBL1 and HBL6, we assessed real-time cellular 
respiration using the XF Extracellular Flux Analyser upon 
sequential injection of specific mitochondrial chemical 
probes to the culture medium [30]. First, the decrease in 
oxygen consumption rate (OCR) following addition of the 
complex V inhibitor, oligomycin, was used to calculate ATP-
linked respiration and proton leak respiration. Next, carbonyl 
cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP), a 
protonophore, was added to collapse the inner membrane 
gradient, driving the electron proton chain to function to 
its maximal rate, and maximal respiratory capacity was 
calculated by subtracting non-mitochondrial respiration from 
the FCCP OCR. Finally, addition of the complex III inhibitor 
antimycin A, together with the complex I inhibitor rotenone, 
resulted in the arrest of the electron proton chain function, 
allowing quantification of non-mitochondrial respiration. 
The mitochondrial reserve capacity was then calculated 
by subtracting basal respiration from maximal respiratory 
capacity (Supplementary Figure S1A). The maximal 
respiratory capacity, elicited by exposure to FCCP, appeared 
much more pronounced in HBL6 compared to BCBL1 
(Figure 1A). Besides, the spare respiratory capacity, an index 
of the efficiency of the electron transport chain to respond 
to energy demand and a predictor of the ability of cells to 
resist stressful conditions [31], reported to be reduced by 
oncogenic transformation [32, 33], was significantly lower 
in BCBL1 compared to HBL6 (Figure 1B). This reduced 
mitochondrial reserve capacity suggests that BCBL1 cells 
are more prone to increase glycolysis in hypoxic condition. 
Thus, we next estimated the extracellular acidification 
rate (ECAR), which correlates with the rate of glycolysis 
because of the by-product lactic acid, in BCBL1 cells. We 
observed that these cells indeed display a high basal aerobic 
glycolysis, assessed by ECAR (Figure 1C), together with 
low oxidative phosphorylation (Figure 1D). In the presence 
of the well-known hexokinase (HXK) inhibitor 2-DG [34–
36], we observed reduction in extracellular acidification, 
due to the block of glycolytic flux, as expected (Figure 1C). 
Interestingly the ratio between OCR and ECAR in basal 
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condition was significantly increased in presence of 2-DG 
compared to glucose only (Figure 1D). This value is an index 
of the relative contribution of glycolysis or mitochondrial 
activity on cellular metabolism and suggests that, in presence 
of 2-DG inhibition, a reversal of the Warburg effect is 
occurring [37]. Indeed as ECAR dropped by about 70%, 
the relative OCR level progressively increased, suggesting 
that mitochondria respiration is fueled through an alternative 
carbon source (Figure 1D). To substantiate this observation, 
we performed an indirect evaluation of the mitochondrial 
ATP production assessing the mitochondrial membrane 
potential fluctuations in response to oligomycin. In the 
presence of 2-DG, mitochondrial hyperpolarization boosted 
up, indicating an augmented production of mitochondrial 
ATP, which inversely correlates with the Warburg effect 
(Supplementary Figure S1B).
PEL cells grow in body cavities, i.e. in hypoxic 
conditions [28, 29]. It was therefore tempting to ask 
whether adaptation to such hostile setting makes PEL 
cells even more reliant on glycolysis for their energy 
requirements, and thus more vulnerable to inhibitors 
that target this metabolic pathway. Accordingly, we 
analyzed the glycolytic flux of PEL cells cultured in 
low oxygen. A boost in the secretion of lactate in the 
culturing medium (Figure 1E), paralleled by an increase 
in the mRNA expression of glycolytic enzymes pyruvate 
kinase PKM1 and PKM2 (Figure 1F), suggested 
that growing in low oxygen increases the glycolytic 
metabolism of these cells, although this might be due 
also to an hypoxia-dependent increase of the lactate 
transporter, the monocarboxylate transporter 1 MCT1 
[38], whose expression in these cells is indeed low 
Figure 1: Hypoxia increases the glycolytic flux in PEL cells. Before the assay, the cells were counted and seeded at 150.000 cell/
well in XF96 culture plates. The oxygen consumption rate (OCR) was analyzed in real time by the XF96 analyzer in normoxia, under 
basal conditions and after sequential addition to the assay medium, through injection ports in the sensor cartridge, of 2 μM oligomycin A, 
1 μM FCCP, and 1 μM rotenone + 1 μM antimycin A (final concentrations), to determine max respiratory capacity (OCR after injection 
of 1 μM FCCP) A. and spare respiratory capacity (OCR after injection of 1 μM FCCP minus basal OCR) B. Acidification of the growth 
medium (ECAR) of BCBL1 cells was measured in the absence (basal) or presence of 2-DG for 24 hours, as indicated. Addition of 2-DG to 
the medium drops ECAR by about 70%, due to HXK inhibition C. while the Relative Oxygen Consumption is shown by the OCR/ECAR 
ratio D. The level of lactate in the culture media of BCBL1 and HBL6 cells grown in normoxia or in hypoxia for 24 hours was measured 
as described in Methods. Proliferating cells grown in hypoxia divert glucose to lactate, resulting in increased lactate production. The data 
are expressed as the mean ± S.D. of three different replicates E. Cell pellets from the above experiment were analyzed by RT-PCR for the 
expression of the glycolysis rate-limiting enzymes PKM1 and PKM2 F. Where indicated, paired t-Test was performed on each mean value. 
p = 0.05.
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(Figure 2G). On these bases, we decided to analyze 
the cytotoxic effect of 2-DG on the above cell lines 
cultured in normoxia or hypoxia. Cells were incubated 
for 24 hours with increasing concentrations of 2-DG, 
followed by MTT assay. As expected, cell viability 
was inhibited in a dose-dependent manner by 2-DG 
(Figure 2A). Besides, hypoxia largely potentiated 
cell sensitivity to 2-DG [39], dropping cell viability 
at a lower dose (Figure 2A). Next, we compared 
the effect of 2-DG with that of molecules targeting 
different steps of glycolysis [40]. These included 
3-bromo-pyruvate (3-BrPA) [41, 42], which targets 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and HXK [43]; oxamate, which inhibits lactate 
dehydrogenase (LDH) [44, 45], and dichloroacetate 
(DCA), which acts instead by reversing the cancer-
associated suppression of pyruvate dehydrogenase 
(PDH) through inhibition of pyruvate dehydrogenase 
kinase, thereby promoting the mitochondrial oxidation 
of pyruvate [46], and lonidamine [42, 47, 48], which 
inhibits HXK. To exclude potential alteration of cellular 
sensitivity to cytotoxic drugs due to a reduction in 
their ability to proliferate, viability of untreated cells 
was assessed by MTT after culturing for 24 hours in 
oxygen-deprived or normoxic conditions and found 
to be not statistically significant (average log2 fold 
change between the hypoxia and normoxia MTT values 
0.074 ± 2.56; 2-tailed paired t-test of hypoxia versus 
normoxia values = 0.48). Lonidamine (Figure 2B) and 
3-BrPA (Figure 2C) had no effect on cell viability even 
at very high concentration, of no clinical significance, 
and longer incubation times (not shown). Importantly, 
Figure 2: PEL cells are sensitive to glycolytic inhibitors. BCBL1 and HBL6 cells were treated for 24 hours with increasing 
concentrations of 2-DG A. lonidamine B. 3-BrPA and 3-BrOP C. DCA D. oxamate E. MTT assays were performed in triplicates. The 
graphs show the mean ± S.D. F. Quantification of sub G0-G1 cells was carried by PI staining followed by flow cytometry analysis, upon 
treatment with 2-DG (2 mM), oxamate (40 mM) and DCA (30 μM) for 24 hours under hypoxia or normoxia. G. mRNA level of the glucose 
transporter MCT-1 was measured by RT-PCR in HBL6, BCBL1 and CEM cell lines.
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however, viability was markedly diminished in both 
cell lines following treatment with DCA (Figure 2D) 
and oxamate (Figure 2E). In the case of oxamate, the 
effect was further strengthened by hypoxia, similar 
to what observed with 2-DG (Table 1A). Thus, the 
ability of 2-DG, oxamate and DCA to cause apoptotic 
cell death was explored measuring the proportion of 
sub-G1 cells by flow cytometry. Cells cultured either in 
hypoxia or in normoxia had comparable basal level of 
apoptosis (about 5%). However, upon administration of 
equal doses of drugs, cells cultured in hypoxia in the 
presence of 2-DG or oxamate displayed more abundant 
apoptosis (Figure 2F), whereas, similar to what observed 
in the viability assay, DCA induced the same proportion 
of apoptosis in both normoxia and hypoxia (Figure 
2F). Besides, we speculated that as both 3-BrPA and 
Lonidamine are transported into the cell through MCT1 
[49, 50], these cell lines might express low amounts 
of the MCT1 protein and would be for this reason 
inherently resistant even to high concentration of the 
drugs. RT-PCR analysis confirmed that this is indeed the 
case, as both HBL6 and BCBL1 cells display very low 
levels of MCT1 transcript, compared to that found in 
cell lines sensitive to 3-BrPA such as the lymphoblastic 
leukemia cell line CEM (Figure 2G). Thus, because of 
its better cell permeability and chemical stability, the 
Table 1: (A) Hypoxia affects the EC50 of glycolysis inhibitors in PEL cells. 
A
BCBL1 HBL6
Drug Molecular target EC50 21% O
2
EC50 1% O
2
EC50 21% O
2
EC50 1% O
2
2-deoxyglucose HXK 6.63 ± 2.98 mM 1.51 ± 0.16 mM 5.10 ± 0.68 mM 2.43 ± 0.24 mM
sodium-oxamate LDH-A 76.40 ± 2.42 mM 44.76 ± 4.33 mM 62.78 ± 3.64 mM 54.82 ± 3.21 mM
lonidamine HXK N.I. at 100 μM N.I. at 100 μM N.I. at 100 μM N.I. at 100 μM
3-bromopyruvate HXK, GAPDH 175.74 ± 11.14 
μM
232.39 ± 11.14 
μM
3- bromo-pyruvate 
propyl ester HXK, GAPDH 34.39 ± 6.13 μM 38.13 ± 3.08 μM 43.86 ± 1.93 μM 52.61 ± 2.28 μM
dichloroacetate PDK 25.78 ± 1.29 μM 25.29 ± 0.70 μM 25.31 ± 0.92 μM 24.45 ± 2.88 μM
B
BCBL1
Drug Molecular target EC50 21% O
2
EC50 1% O
2
PF-04691502 PI3K/mTOR 1.44 ± 0.4 μM 1.06 ± 0.2 μM
Akti 1/2 Akt 1.32 ± 0.15 μM 0.92 ± 0.11 μM
C
BCBL1
Drug 1 Drug 2 C.I. (50;75;90) 21% O
2
C.I. (50;75;90) 1% O
2
 
PF-04691502 2-deoxyglucose 0.34;0.36;0.39 0.67;0.46;0.49
Akti 1/2 2-deoxyglucose 0.37;0.40;0.29 0.68;0.53;0.60
CBL1 and HBL6 cells were treated with increasing concentrations of 2-DG, lonidamine, 3-BrPA, 3-BrOP, DCA, oxamate as 
described in Figure 2, panels A to E. MTT assays were performed in triplicates, and the EC50 in normoxia (21%) and in hypoxia 
(1%) was calculated. Mean values and S.D. are indicated. (B) Hypoxia affects the EC50 of PI3K/mTOR and Akt inhibitors in 
PEL cells. BCBL1 cells were treated for 24 hours with increasing concentrations of Akti 1/2 or PF-04691502, as described in 
Figure 4 panels B and C respectively. Then MTT assays were performed in triplicates, and the EC50 in normoxia (21%) and in 
hypoxia (1%) was calculated. Mean values and S.D. are indicated. (C) Combined treatment with 2-DG and PI3K/mTOR or Akt 
inhibitors displays synergistic cytotoxicity in PEL cells. BCBL1 cells were treated for 24 hours with 2-DG in association with 
PF-04691502 or with Akti 1/2 at the concentrations reported in Figure 6, panels A and C respectively. The CI in normoxia (21%) 
and in hypoxia (1%) was calculated with the CalcuSyn algorithm.
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ester pro-drug of 3-BrPA, 3-bromo-pyruvate propyl 
ester (3-BrOP) was used instead. 3-BrOP showed very 
high citotoxicity at low dosage (Figure 2C), suggesting 
that the ability of 3-BrOP to enter the cells and release 
3-BrPA via hydrolysation by cellular esterases accounts 
for the > 10 fold difference in the potency of the two 
compounds. However, its efficacy was not improved by 
hypoxia (Table 1A).
Hypoxia inhibits the mTOR pathway in PEL 
cells
Cellular responses to hypoxia are known to reduce 
chemotherapeutic sensitivity through various direct or 
indirect mechanisms acting on survival pathways [51], 
such as the PI3K/Akt/mTOR signaling cascade. To get 
more insights into this issue, PEL cells grown for 24 hours 
either in normoxia or in hypoxia were profiled by means of 
reverse phase protein array analysis (RPPA) and Western 
blotting, with a panel of antibodies recognizing primarily 
phosphorylated epitopes of the PI3K/Akt/mTOR signaling 
pathway (Figure 3A–3C). HeLa cells were used as positive 
control, since in these cells the above pathway is known to 
be constitutively active [52]. The result not only confirms 
that the pathway is constitutively activated in all samples 
but also demonstrates that hypoxia negatively affects it 
at the level of mTORC1 and its downstream substrate 
P70S6K (Figure 3B). These results were confirmed 
by Western blotting (Figure 3C and Supplementary 
Table S2A). Stabilization and activation of the Hypoxia 
Inducible Factor 1 (HIF1) was monitored as a readout of 
hypoxia, assessing the expression of the regulatory subunit 
HIF1α (Figure 3C and Supplementary Figure S2B–S2C). 
HIF1 has been demonstrated to be a master regulator 
Figure 3: Hypoxia affects the PI3K/Akt/mTOR pathway at the mTORC1 level. A. Activation of the PI3K/Akt/mTOR 
pathway was analyzed by RPPA in BCBL1 and HBL6 cells, and phosphorylation of key molecules was compared with HeLa cells. B. RPPA 
comparison of the phosphorylation status of the indicated signaling molecules in BCBL1 cells grown in normoxia or in hypoxia. C. Equal 
amounts of cellular protein extracts from (B) were resolved by SDS-PAGE and probed with the indicated antibodies. PDK1 S241, Akt 
T308, Akt S473 are a readout of Akt downstream signaling activation. P70S6K T389 is a readout of mTOR activation. HIF1α was is a 
readout of hypoxia. Equal loading was confirmed by anti-β-actin.
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of the switch in glucose metabolism from oxidative 
respiration to aerobic glycolysis [53, 54]. HIF1-mediated 
hypoxia response and the PI3K/Akt/mTOR pathway 
have demonstrated an intimate mutual dependence, and 
can act in an integrated way, even though the modality 
of the interaction is largely dependent on cell-type and 
experimental set-up [55]. Opposite to what reported 
previously in different cell models, in PEL cells forced 
expression of a constitutively active form of Akt, myrAkt 
[56], which inactivates TSC1/2 by direct phosphorylation, 
was not sufficient to stabilize HIF1α in normoxia 
(Supplementary Figure S2A). On the other hand, mTOR 
inhibition by rapamycin, which targets mTORC1, and 
by torin1, which blocks both mTORC1 and 2, decreased 
hypoxia-induced HIF1α levels (Supplementary Figure 
S2B), indicating that the mTOR pathway is necessary 
for the full realization of the HIF-mediated response to 
hypoxia in these cells.
Hypoxia alters PEL cells sensitivity to inhibitors 
of the PI3K/Akt/mTOR pathway
PI3K/Akt/mTOR is a converging hub of both 
oncogenic and metabolic signaling [57–59]. Recently it 
has been shown to strongly affect cellular metabolism, 
favoring and supporting the Warburg phenotype in cancer 
cells both directly and indirectly: as a target of multiple 
growth factors, PI3K stimulation can lead to chronic 
activation of Akt in cancer cells, which in turn can directly 
increase the expression of glucose transporters and 
glycolytic enzymes [60–65]. Besides, PI3K can influence 
cell metabolism indirectly through the stimulation of 
mTORC1, that in turn controls amino acid metabolism 
and protein translation [66]. Importantly, the dual PI3K 
and mTOR inhibitor NVPBEZ235 was previously 
shown to counteract the glycolytic phenotype of the 
BCBL1 PEL cell line and to delay tumor progression in a 
xenograft model of PEL [10]. The high activation of Akt, 
moreover, has been recently shown to drive glycolysis 
of leukemic cells [67]. Therefore, we investigated the 
effect of a panel of drugs targeting either Akt, namely 
the allosteric inhibitors Akti 1/2 and MK2206, or mTOR, 
namely torin1, or both PI3K and mTOR, namely the 
abovementioned NVPBEZ235 and the second generation 
dual PI3K and mTOR inhibitor PF-04691502, on the 
glycolytic BCBL1 cell line. All the above drugs inhibited 
their target efficiently, as demonstrated by the decreased 
phosphorylation of Akt S473 and P70S6K T389 (Figure 
4A and Supplementary Table S2B–S2C), indicating that in 
PEL cells this pathway is indeed druggable. Furthermore, 
we assessed that they were all cytotoxic on PEL cells, with 
an EC50 in the nanomolar or low micromolar range. In 
particular, given the perturbation of the pathway during 
hypoxia, which might potentially alter cellular sensitivity 
to the drugs, we compared the cytotoxic activity of the 
compounds in normoxia and in hypoxia. It is worth noting 
that while torin1, MK2206 and NVPBEZ235 effectiveness 
was barely affected (Supplementary Figure S3A–S3C 
and Supplementary Table S1), hypoxia did enhance 
cytotoxicity of both the Akti 1/2 and the PF-04691502 
inhibitors (Figure 4B–4C), in good agreement with the 
significantly lower EC50 values displayed by the same two 
drugs in hypoxia. The results are summarized in Table 1B 
and Supplementary Table S1. Next, to ascertain that the 
effects of the inhibitors were not due to off-target action, 
the expression of Akt1 and 2 (the Akt isoforms detectable 
in these cells) was silenced by a specific siRNA directed 
to a sequence common to Akt 1 and Akt2, and compared 
to scramble siRNA. As expected, the downregulation 
of Akt expression dramatically decreased cell viability 
(Figure 4D).
Disruption of the PI3K/Akt/mTOR pathway in 
PEL cells affects glucose metabolism
We next investigated whether modulation of the 
pathway by the indicated drugs may be useful to control 
PEL cell metabolic rewiring. BCBL1 cells were treated 
as described above, then the glucose-to-lactate flux was 
calculated, based on the ECAR of the culture media. 
Remarkably, all treatments caused a reduction of ECAR, 
i.e. of glycolysis, to an extent close to that obtained with 
2 mM 2-DG (Figure 5A), with the exception of MK2206 
(Supplementary Figure S4A). In agreement with this 
finding, we observed that, although glycolysis in basal 
condition is already very high in these cells, an additional 
increase of Akt activity through forced expression of its 
constitutively active form, led to a small but significant 
extra boost of ECAR (Figure 5A). Moreover, when cells 
were grown in low oxygen, all treatments significantly 
counteracted the production of lactate (p < 0.05) (Figure 
5B). Similar results were obtained by means of silencing 
Akt with specific siRNA (Figure 5C). We concluded 
therefore that the effects described above, triggered by 
addition of these drugs to BCBL1 cells, are indeed due to 
the inhibition of the activity of their target kinases.
This observation confirms the involvement of the 
PI3K cascade in the regulation of glucose metabolism 
in PEL cells. As a consequence of the reduced glucose 
utilization, also OCR appears slightly inhibited in both basal 
condition (Figure 5D) as well as upon FCCP-stimulated 
maximal respiration (Figure 5E). Notably the OCR/ECAR 
ratio remains mostly unchanged, suggesting that inhibition 
of the PI3K cascade alone does not revert the Warburg effect 
characterizing this cell line (Figure 5F). Quite unexpectedly, 
however, we found that in combination with 2-DG these 
compounds increased both basal and max respiration rate 
(Figure 5D–5E). Accordingly, 2-DG combined with PF-
04691502 or with Akti 1/2 resulted in a significant (p < 0.05) 
boost of the OCR/ECAR ratio (Figure 5F). In particular, the 
combination of 2-DG with PF-04691502 as well as with 
Akti 1/2 was characterized by high oxygen consumption, 
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and resulted in a significant (p < 0.05) shift from aerobic 
glycolysis towards a more oxidative respiration (Figure 5E). 
We asked whether such a shift might render cancer cells 
more susceptible to induction of apoptosis. Therefore we 
next tested the cytotoxicity of these drug combinations on 
PEL cells by MTT assay. The association with 2-DG clearly 
drops cell viability (Figure 6A–6E), with a concentration-
dependent effect, as indicated by the combination index (CI) 
values (Table 1C), calculated according to Chou&Talalay 
[68]. The results point to a strong synergism (CI < 0.5) of 
2-DG in association with Akti 1/2 or with PF-04691502, 
both in normoxia and in hypoxia (Table 1C). In particular, 
hypoxia further diminishes cell viability by these 
combinations, which thus might prove useful as a novel 
therapeutic approach for PEL. However, because these 
results were obtained by means of a metabolic assay based 
on mitochondrial activity, which might be affected by the 
drugs, apoptosis triggered by single or combined treatments 
was assessed by Annexin V staining. The result demonstrates 
that 2-DG indeed potentiates the effect of both Akti 1/2 and, 
to a greater extent, PF-04691502. Importantly, it also shows 
that a low oxygen environment further augments the number 
of Annexin V positive cells (Figure 6E), strengthening the 
concept that this type of drug association should be taken 
into account as a novel approach in PEL therapy.
Due to the recently demonstrated shielding effect of 
the mesothelium on lymphoma progression [69], we then 
asked whether the mesothelial microenvironment protects 
Figure 4: Hypoxia influences BCBL1 cells sensitivity to Akt or PI3K/mTOR inhibition. A. BCBL1 cells were cultured 
for 24 hours in hypoxia or normoxia and treated with PF-04691502 0.625 μM, NVPBEZ235 50 nM, Akti1/2 200 nM, torin1 100 nM and 
MK2206 1 μM. Equal amounts of cellular protein extract were resolved by SDS-PAGE and probed with the indicated antibodies. Equal 
loading was confirmed by anti-β-actin. Cell viability upon 24 hours treatment with Akti1/2 B. or PF-04691502 C. was monitored by MTT 
assay, as described previously. D. Cells were transfected with siRNA directed to human Akt1 and 2, or with scramble siRNA, by means of 
the Amaxa nucleofection system using the nucleofector solution V, then cell viability was detected by MTT. E. Equal amounts of cellular 
protein extracts form samples described in (D) were resolved by SDS-PAGE and probed with anti-Akt1 or anti-Akt2. Equal loading was 
confirmed by anti-β-actin.
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against 2-DG+PF-04691502-facilitated apoptosis. To 
mimic the physiological microenvironment, BCBL1 cells 
were co-cultured with primary human mesothelial cells 
(HMC) for 48 hours, a condition sufficient to highlight 
the pro-survival effect of HMC on BCBL1 cells (Figure 
6F). Then cells cultures were subjected to treatment with 
DMSO vehicle (mock) or with a combination of 2-DG and 
PF-04691502 for 24 or 48 hours. Total apoptosis of the 
BCBL1 population was determined by means of Annexin 
V staining. While HMC co-culture proved able to protect 
PEL cells from apoptosis in basal condition, it is clear 
that it is not sufficient to abrogate the pro-apoptotic effect 
of the drugs nor to diminish its efficacy (Figure 6F and 
Supplementary Figure S5A–S5B).
Figure 5: 2-DG inhibition of glycolysis combined with Akt and PI3K/mTOR inhibition results in increased oxidative 
metabolism. BCBL1 cells, treated for 24 hours with vehicle (CTRL), 0.625 μM PF-04691502, 200 nM Akti1/2, 1 mM 2-DG as indicated, 
either in normoxia (A) or in hypoxia (B). Panel A. cells were counted and plated at 150.000 cell/well in XF96 culture plates prior to the 
assay, then ECAR was calculated in control cells, upon addition of 2-DG or PI3K/Akt/mTOR inhibitors for 24 hours, as well as in BCBL1 
cells transiently transfected (24 hours) with empty vector or with the constitutively active myrAkt vector. Panel B. the level of lactate in 
the culture medium of BCBL1 grown in hypoxia for 24 hours was measured as described in Methods. The data are expressed as the mean 
± S.D. of three different replicates. Panel C. BCBL1 cells were transfected either with siRNA to Akt1/2 as in Figure 4D, or with empty 
vector or myr-Akt as in (A) Then secreted lactate was assayed in the supernatant. Panels D. and E. represent Basal Respiration and Max 
Respiratory Capacity, respectively, in cells exposed to vehicle (DMSO), 0.625 μM PF-04691502, 200 nM Akti1/2 alone (pale blue bars) or 
in the presence of 2 mM 2-DG (dark blue bars). Panel F. shows the Relative Oxygen Consumption by the OCR/ECAR ratio, in the same 
setting as in (D) and (E). Each experiment was performed at least three times. Where indicated, unpaired t-Test was performed on each 
mean value.
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Finally to investigate the toxicity of the proposed 
drug combinations on normal cells, BCBL1 cells were 
grown for 24 hours in the presence of 2-DG ± PF-
04691502 or Akti 1/2, and the viability, assessed by 
Annexin V/PI staining, was compared to that of normal 
human B (CD19+) and T (CD3+) lymphocytes from 
healthy donors. It is very interesting to note that in both 
cases drugs appear to exert little toxicity on normal human 
lymphocytes, compared to PEL cells (Figure 7B–7D), 
suggesting some degree of specificity towards PEL cells.
DISCUSSION
Remodeling of energy metabolism from oxidative 
phosphorylation to oxygen-independent aerobic glycolysis 
is becoming a sensible area for drug targeting. PEL is a 
B-cell NHL characterized by a very poor prognosis, with 
a median survival of six months after the diagnosis and 
no standard therapy [1–4]. In agreement with a previous 
report [26], we detail here that PEL cells preferentially 
channel glucose towards lactate production even in 
Figure 6: Hypoxia strenghtens the cytotoxicity of the drug treatment. BCBL-1 cells were grown in normoxia or in hypoxia, 
treated with 2-DG alone or in combination with Akti1/2 A, B. or PF-04691502 C, D. at the indicated concentrations, for 24 hours. Graphs A 
to D show the MTT response relative to controls. CI was calculated with the CalcuSyn algorithm. E. From the same experimental setting, 
total apoptosis of cells treated with 2 mM 2-DG with or without 625 nM PF-04691502 or 1 μM Akti1/2 was assessed by Annexin V staining. 
F. BCBL1 cells were co-cultured for 24 or 48 hours with HMC in a medium additioned with vehicle (mock), with 625 nM PF-04691502 
or with 1 μM Akti1/2. Total apoptosis was calculated as the mean percentage of Annexin V positive BCBL1 cells in each condition, as 
indicated.
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the presence of oxygen, and thus display a glycolytic 
metabolism. A large body of evidence has shown that 
the glycolytic phenotype in cancer cells is due to active 
glycolysis prevailing over mitochondrial respiration 
rather than to defects in mitochondrial function [70]. 
The observation that proliferation and tumorigenicity 
of cancer cells can be inhibited blocking glycolysis, 
however, suggests that enhanced oxidative respiration is 
not sufficient to meet the requirement of cancer growth 
and that glycolysis is a target of cancer therapy [71–73]. 
In our work, we confirm that BCBL1 cells maintain the 
ability to produce ATP by mitochondrial respiration, and 
that inhibition of glycolysis by 2-DG is toxic to these cells. 
We also demonstrate that 2-DG as well as other glycolysis 
inhibitors such as oxamate are particularly effective 
against PEL in low-oxygen settings, a condition that 
mimics the highly hypoxic environment of body cavities 
[28–29]. This indicates that in hypoxia PEL cells are even 
more reliant on glycolysis for their energy requirements 
and thus intrinsically more exposed to its inhibition. 
Although its potential as monotherapy is poor, in spite of 
the promising results in vitro and in animal models as well 
as of its excellent safety profile as anti-cancer drug, 2-DG 
has been shown to enhance the efficacy of many drugs 
when administered in combination [74, 75].
The PI3K/Akt/mTOR signaling can favor and 
support the Warburg phenotype in cancer cells both 
directly and indirectly. PI3K stimulation by multiple 
growth factors can lead to chronic activation of Akt in 
cancer cells, which directly increases the expression 
of glucose transporters and glycolytic enzymes, and in 
turn glucose metabolism in cancer cells versus normal 
cells [61, 62]. In particular, Akt has been shown to 
regulate HXK expression, activity, and mitochondrial 
interaction [76], as well as the localization of the glucose 
transporter GLUT1 to the plasma membrane [60]. In 
addition, phosphorylation of phosphofructokinase-2 
by Akt [77] drives allosteric activation of PFK1. Akt 
activity correlates to the degree of a high level of aerobic 
glycolysis without increasing oxygen consumption 
[62], and has been recently shown to drive glycolysis of 
leukemic cells [67]. In previous studies, the efficacy of 
the mTOR inhibitor rapamycin in PEL cells in culture 
and in a xenograft PEL model was limited by the rapid 
emergence of drug resistance [9], whereas dual targeting 
of PI3K and mTOR by the inhibitor NVP-BEZ235 
gave better results [10]. In this study the animal PEL 
model was obtained by subcutaneous injection of PEL 
cells, though, rather than by peritoneal engraftment, 
which would reproduce the in vivo pathology more 
Figure 7: Glycolysis inhibition combined with Akt or PI3K/mTOR inactivation displays low cytotoxicity to primary 
lymphocytes from healthy donors. BCBL1 and peripheral blood mononuclear cells (PBMCs) were treated for 24 hours as indicated, 
then stained with PI and Annexin V followed by flow cytometry analysis. PBMCs from healthy donors were labeled with anti-CD3+ or 
with anti-CD19+ to detect T-lymphocytes and B-lymphocytes respectively. The graphs show the percentage of viable (double negative PI/
Annexin V) and apoptotic (PI negative/Annexin V positive) BCBL1 cells A. CD3+ cells B. or CD19+ cells C. The data are expressed as 
the mean ± S.D. of three different replicates.
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closely. Taking the view that alteration of intracellular 
signaling through the PI3K pathway is deemed crucial 
to achieve a cancer metabolic phenotype through the 
Warburg effect, our study highlights the previously 
unreported observation that pathway-specific inhibitors 
targeting either PI3K/mTOR or Akt counteract lactate 
production to an extent similar to that obtained by 2-DG, 
as indicated by the shift of the ECAR. Remarkably, in 
these cells PF-04691502 is able not only to significantly 
decrease the extracellular acidification but also to 
deeply enhance the mitochondrial respiration rates, thus 
switching aerobic glycolysis towards a more oxidative 
metabolism. As expected, all drugs dramatically 
decrease cell viability. Most importantly, both effects are 
enhanced by association with 2-DG, pointing to a strong 
synergistic action, both in normoxia and in hypoxia. 
Although the rationale of this synergy is not completely 
understood, it is worth remembering that 2-DG also 
increases oxidative stress, affects protein glycosylation, 
and therefore causes aberrant GlcNAcylation of 
proteins and accumulation of misfolded proteins in 
the endoplasmic reticulum, leading to autophagy and 
ER stress response [78, 79]. This last effect may be 
particularly relevant to our work, as it has been recently 
demonstrated that Akt inhibition potentiates toxicity 
induced by 2-DG through ER stress response in acute 
lymphoblastic leukemia by enhancing the unfolded 
protein response. [80]. Moreover, it has been shown 
recently that 2DG can also modify the expression 
profile of cancer cells [81]. In particular, it was claimed 
to induce the transient expression of p21 and a stable 
expression of p53, together with cell cycle arrest at 
G0/G1 phase and apoptosis through the intrinsic, 
mitochondrial pathway in colorectal cancer cells [81]. 
Interestingly these effects were totally independent of 
its inhibitory effect on either hexokinase or ATP levels. 
All together these studies provide key insights about 
processes, essential for the biological properties of 
2-DG, that act beyond the metabolic block, and might 
prompt cancer cells to the pro-apoptotic action of the 
drugs used in our study.
Moreover, it is particularly important that the pro-
apoptotic function of this drug association also prevails 
over the shielding action of the HMC in the HMC-BCBL1 
co-culture performed to mimic the PEL microenvironment 
[69]. Finally, it is worth remembering that we have shown 
here that the above drug associations exert very low 
toxicity in normal human B and T lymphocytes, compared 
to PEL cells, suggesting some degree of specificity 
towards cancer cells. Thus, all together, our results open 
a new therapeutic approach for PEL. Notably, because 
the above combinations are highly effective also under 
normoxic conditions, they could be extended to other 
B-NHL characterized by a glycolytic phenotype.
MATERIAL AND METHODS
Chemicals and reagents
Akti 1/2 was purchased from Calbiochem, 
rapamycin, 2-deoxy-D-glucose (2-DG), dichloroacetate 
(DCA) and 3-bromo pyruvate (3-BrPA), were from 
Sigma-Aldrich, PF-04691502, torin1 and MK2206 were 
from Selleckchem, lonidamine from LTK Laboratories and 
NVPBEZ235 were from Axon Medchem. A derivative of 
3-BrPA, 3-bromo-2-oxopropionate-1-propyl ester (3-
BrOP), was synthesized by esterification of 3-BrPA with 
1-propanol (Sigma-Aldrich) as previously described [82]. 
siRNA to Akt1 and 2 were from Origine (Rockville, MD, 
USA).
Cell culture and transfection
PEL cell lines BCBL1 and HBL6 were maintained 
in RPMI1640 supplemented with 20% heat-inactivated 
fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml 
12 streptomycin, 2 mM L-glutamine. Both cell lines are 
KSHV-positive; HBL6 are also EBV-positive. Cells 
were grown under either normoxia (21% O2, 5% CO2) or 
hypoxia (1% O2, 5% CO2) at 37°C for the indicated times 
and drug concentrations. Low O2 tension was obtained 
using either a Hypoxia Chamber (StemCell Technologies) 
or the INVIVO200 hypoxia workstation (Ruskinn 
Technology Ltd., UK). Transfection of BCBL1 cells was 
performed using the Amaxa nucleofection system (Amaxa, 
Cologne, Germany). Briefly, 5–10 × 106 cells were 
resuspended in nucleofector solution V prior to addition of 
DNA (CMV6-HA-myrAkt, CMV6 empty vector, siRNA 
to Akt 1 and 2 or scramble siRNA), then transferred to 
an Amaxa-certified cuvette and transfected using program 
T-001. Cells were examined for the expression of 
transfected genes 24 to 48 hours post transfection.
Western blotting and RPPA analysis
Samples were extracted in TPER reagent (Pierce, 
Rockford, IL, USA). For Western blotting, 30 μg of total 
lysates were separated by 10% SDS-polyacrylamide gel 
electrophoresis and transferred to PVDF membrane 
(Millipore) as previously described [83]. Array 
assembly, printing, staining and analysis were performed 
as described [84–86]. Antibodies against phosphorylated 
epitopes were from Cell Signaling Technologies. Anti-
β-actin was from Sigma Aldrich. Anti-HIF1α was from 
BD Biosciences. Differences in basal phosphorylation of 
treated samples were compared by calculating the ratio 
of each sample’s SI (signal intensity) divided by vehicle- 
(DMSO) or drug-treated sample’s SI. To determine the 
significance of the difference in mean of treated samples 
we used a Paired student’s t test with a P-values = 0.05.
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MTT assay
Viability of PEL cells treated with various 
inhibitors or the appropriate vehicle as a negative 
control was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT)- based 
colorimetric assay as previously described [87]. Where 
indicated, effective dose 50s and combination index 
were calculated following the Chou-Talalay method [68] 
and the softwares GrafIt and CompuSyn (ComboSyn 
InC.)
Lactate assay
Cells were rinsed in fresh media and grown for 
6 or 24 hours in the presence or absence of inhibitors 
as indicated. Media samples were then collected, flash-
frozen in liquid nitrogen and immediately stored at –80°C 
until the time of the assay. Lactate levels in media were 
measured using a Lactate Assay Kit (Eton Bioscience Inc.) 
according to manufacturer instructions.
Flow cytometry analysis
For cell cycle analysis, 5 × 105 cells were centrifuged 
at 1200 rpm for 8 minutes, washed with PBS and fixed with 
cold 70% EtOH for 2 hours, and incubated with 25 μg (1 
μl) of RNAse (Sigma Aldrich, 25 μg/μl) for 1 hour at 37°C. 
PI (25 μl, 5 mg/ml, Sigma Aldrich) was added fresh prior 
to analysis. For detection of apoptosis, 1 × 106 cells were 
washed twice with PBS and stained with Annexin V–FITC 
and PI in 1X binding buffer (10 mM HEPES, pH 7.4, 140 
mM NaOH, 2.5 mM CaCl2) for 15 min at room temperature 
in the dark. Both early apoptotic (Annexin V+, PI-) and late 
(Annexin V+ and PI+) apoptotic cells were included in cell 
death determinations. Annexin V- and PI-negative cells are 
viable cells. The analysis was performed on a FACSCalibur 
(BD Bioscences, NJ, USA).
BCBL1-mesothelial cells co-culture
Primary human mesothelial cells (HMC) were 
isolated and cultured as previously reported [69]. To 
evaluate the activity of 2-DG and PF on BCBL1 cells in 
a context mimicking the intracavitary environment, 2 × 
105 BCBL1 cells were co-cultured with subconfluent cells 
first passage HMC in 6-well plates with or without drug 
treatment for 48 hours. Total apoptosis of BCBL1 cells 
was quantified by flow cytometry after Annexin V staining 
(Annexin-V-FLUOS Staining Kit, Roche Diagnostics, 
Mannheim, Germany). Data were analyzed using the 
Kaluza Flow Analysis software (Beckman Coulter). SD 
of the ratio is calculated according to the theory of error 
propagation, as previously reported [88].
RT-PCR
Total RNA extraction was as described [83], using the 
Aurum Total RNA Fatty and Fibrous Tissue kit (Bio-Rad, 
Hercules CA, USA) according to manufacturer’s instructions. 
Genomic DNA was removed by DNase treatment. 
MCT-1 and isoform-specific PKM1 (NM_182470) and 
PKM2 (NM_002654) forward and reverse primers were 
as follows: 5-TTTCTTTGCGGCTTCCGTTGTTG-3; 
antisense, 5-TCAATTTACCCTTCAGCCCCATGG 
for MCT-1; 5′- CTGAGGCAGCCATGTTCC- 3′ and 
5′- CCATGAGGTCTGTGGAGTG- 3′ for PKM1; 
5′- ACTTGGTGAGGACGATTATG- 3′ and 5′- 
CTGCCATCTACCACTTGC- 3′ for PKM2. PCR primers 
were designed using Beacon Designer 2.06 (Premier Biosoft 
International). Real-time amplifications, using SYBR Green 
detection chemistry, were run in triplicate on 96-well 
reaction plates with the CFX96 machine (Bio-Rad).
XF bioenergetic analysis
Oxygen consumption and extracellular acidification 
rates in PEL cells were measured using the Seahorse 
XF96 instrument (Seahorse Biosciences, North Billerica, 
MA) according to the manufacturer's protocols. 24 hours 
after treatment, cells were seeded in a poly-lysine coated 
XF96 microplate at the density of 150000 cells per well, 
for 60 minutes in a 37°C non-CO2 incubator, while 
sensor cartridges were calibrated prior to the start of an 
assay. After adhesion, medium was changed with 175 
μl unbuffered XF assay media at pH 7.4 supplemented 
with 5.5 mM glucose (Sigma), 1 mM sodium pyruvate 
and 1 mM Glutamine. Respiration was measured in four 
blocks of three for 3 min. The first block measured the 
basal respiration rate. Next 2 μM oligomycin was added to 
inhibit complex V (second block). Then 0.3 μM carbonyl 
cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP, 
Seahorse Biosciences, North Billerica, MA) was added to 
uncouple respiration (third block). Finally, 1 μM antimycin 
A and 1 μM Rotenone was added to inhibit complex III 
(forth block). All reagents are from Seahorse Biosciences, 
North Billerica, MA. Immediately after finishing the 
measurements, cells were washed with phosphate-buffered 
saline, fixed with 4% paraphormaldehyde and stained with 
0.1% crystal violet (1 mol/l acetic acid) and absorbance at 
595 nm was measured as index of cell amount.
Measurement of cellular ATP content
Intracellular ATP was measured by bioluminescence 
using a luciferin-luciferase system (ATP bioluminescent 
assay kit CLS II; Roche) as described previously [89]. 
The amount of ATP measured was referred to the protein 
content, determined by the method of Lowry [90], and 
expressed as nmol/mg protein.
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Statistical Analysis
The data were presented as mean ± standard 
deviation, with at least three replicates used for each data 
point. Unless otherwise indicated, a paired Student’s t test 
was performed for each experimental group to assess the 
statistical significance against respective controls.
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